SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/123441"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/123441" > Impact of the metho...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004641naa a2200721 4500
001oai:gup.ub.gu.se/123441
003SwePub
008240528s2009 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/1234412 URI
0247 a https://doi.org/10.1200/JCO.2008.18.14872 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Brugières, Laurence4 aut
2451 0a Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.
264 1c 2009
520 a PURPOSE: To compare the efficacy and safety of two methotrexate doses and administration schedules in children with anaplastic large-cell lymphoma (ALCL). PATIENTS AND METHODS: This randomized trial for children with ALCL was based on the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Muenster 90 (NHL-BFM90) study protocol and compared six courses of methotrexate 1 g/m2 over 24 hours and an intrathecal injection (IT) followed by folinic acid rescue at 42 hours (MTX1 arm) with six courses of methotrexate 3 g/m2 over 3 hours followed by folinic acid rescue at 24 hours without IT (MTX3 arm). This trial involved most European pediatric/lymphoma study groups and a Japanese group. RESULTS: Overall, 352 patients (96% ALK positive) were recruited between 1999 and 2005; 175 were randomly assigned to the MTX1 arm, and 177 were assigned to the MTX3 arm. Ninety-two percent of patients received protocol treatment. Median follow-up time is 3.7 years. Event-free survival (EFS) curves were superimposed with 2-year EFS rates (73.6% and 74.5% in the MTX1 and MTX3 arms, respectively; hazard ratio = 0.98; 91.76% CI, 0.69 to 1.38). Two-year overall survival rates were 90.1% and 94.9% in MTX1 and MTX3, respectively. Only two CNS relapses occurred (both in the MTX1 arm). Toxicity was assessed after 2,050 courses and included grade 4 hematologic toxicity after 79% and 64% of MTX1 and MTX3 courses, respectively (P < .0001); infection after 50% and 32% of courses, respectively (P < .0001); and grade 3 to 4 stomatitis after 21% and 6% of courses, respectively (P < .0001). CONCLUSION: The results of the NHL-BFM90 study were reproduced in this large international trial. The methotrexate schedule of the NHL-BFM90 protocol including IT therapy can be safely replaced by a less toxic schedule of methotrexate 3 g/m2 in a 3-hour infusion without IT therapy.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Pediatrik0 (SwePub)302212 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Pediatrics0 (SwePub)302212 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng
653 a Adolescent
653 a Antimetabolites
653 a Antineoplastic
653 a administration & dosage
653 a Child
653 a Child
653 a Preschool
653 a Dose-Response Relationship
653 a Drug
653 a Drug Administration Schedule
653 a Female
653 a Humans
653 a Infant
653 a Injections
653 a Spinal
653 a Lymphoma
653 a Large B-Cell
653 a Diffuse
653 a drug therapy
653 a pathology
653 a Male
653 a Methotrexate
653 a administration & dosage
653 a Treatment Outcome
653 a Young Adult
7001 a Le Deley, Marie-Cécile4 aut
7001 a Rosolen, Angelo4 aut
7001 a Williams, Denise4 aut
7001 a Horibe, Keizo4 aut
7001 a Wrobel, Grazyna4 aut
7001 a Mann, Georg4 aut
7001 a Zsiros, Jozsef4 aut
7001 a Uyttebroeck, Anne4 aut
7001 a Marky, Ildiko,d 1940u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xmaril
7001 a Lamant, Laurence4 aut
7001 a Reiter, Alfred4 aut
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org
7730 t Journal of clinical oncology : official journal of the American Society of Clinical Oncologyg 27:6, s. 897-903q 27:6<897-903x 1527-7755
8564 8u https://gup.ub.gu.se/publication/123441
8564 8u https://doi.org/10.1200/JCO.2008.18.1487

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy